REFERENCES
- Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol 2003; 73(3)200–210, [PUBMED], [INFOTRIEVE]
- Kalinowski D, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005; 57(4), [CROSSREF]
- Weatherall DJ. The iron-loading anemias. Development of Iron Chelators for Clinical Use, AE Martell, WF Anderson, DG Badman. Elsevier-North Holland, New York 1981; 3–12
- Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89(3)739–761, [PUBMED], [INFOTRIEVE]
- Hoffbrand AV, Pettit JE, Moss PAH. Genetic disorders of hemoglobin. Essential Haematology4th, AV Hoffbrand, JE Pettit, PAH Moss. Blackwell Scientific Publishers, London 2001; 71–83
- Wong C, Richardson DR. β-Thalassaemia: emergence of new and improved iron chelators for treatment. Int J Biochem Cell Biol 2003; 35(7)1144–1149, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pandolfo M. Molecular pathogenesis of Friedreich ataxia. Arch Neurol 1999; 56(10)1201–1208, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Puccio H, Koenig M. Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet 2000; 9(6)887–892, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Richardson DR. Expert Opin Investig Drugs 2003; 12(2)235–245, [PUBMED], [INFOTRIEVE]
- Napier I, Ponka P, Richardson DR. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood 2005; 105(5)1867–1874, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000; 95(9)2776–2779, [PUBMED], [INFOTRIEVE]
- Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem 2004; 11(16)2161–2183, [PUBMED], [INFOTRIEVE]
- Becker E, Richardson DR. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin Med 1999; 134(5)510–521, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Richardson DR, Becker E, Bernhardt PV. The biologically active iron chelators 2-pyridylcarboxaldehyde isonicotinoylhydrazone, 2-pyridylcarboxaldehyde benzoylhydrazone monohydrate and 2‐furaldehyde isonicotinoylhydrazone. Acta Crystallogr C 1999; 55(pt 12)2102–2105, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ponka P, Borova J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 1979; 97(2)317–321, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 1979; 586(2)278–297, [PUBMED], [INFOTRIEVE]
- Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 1998; 131(4)306–315, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bernhardt PV, Chin P, Richardson DR. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy. J Biol Inorg Chem 2001; 6(8)801–809, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Richardson DR, Ponka P. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 1994; 124(5)660–671, [PUBMED], [INFOTRIEVE]
- Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995; 86(11)4295–4306, [PUBMED], [INFOTRIEVE]
- Wong CS, Kwok JC, Richardson DR. The novel iron chelator, 2-pyridylcarboxaldehyde isonicotinoyl hydrazone, is orally active and induces iron excretion in mice. Biochim Biophys Acta 2004; 1739(1)70–80, [PUBMED], [INFOTRIEVE]
- Richardson DR, Mouralian C, Ponka P, Becker E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta 2001; 1536(2–3)133–140, [PUBMED], [INFOTRIEVE]
- Ponka P, Wilczynska A, Schulman HM. Iron utilization in rabbit reticulocytes. A study using succinylacetone as an inhibitor or heme synthesis. Biochim Biophys Acta 1982; 720(1)96–105, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Adams ML, Ostapiuk I, Grasso JA. The effects of inhibition of heme synthesis on the intracellular localization of iron in rat reticulocytes. Biochim Biophys Acta 1989; 1012(3)243–253, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Richardson DR, Ponka P, Vyoral D. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. Blood 1996; 87(8)3477–3488, [PUBMED], [INFOTRIEVE]